Tumor necrosis factor α-converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  de Meijer, Vincent E ^a,b   Le, Hau D ^a,c   Meisel, Jonathan A ^a,c   Sharma, Anisha K ^c   Popov, Yury ^c   Puder, Mark ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; MARIMASTAT; MESSENGER RNA; ADAM PROTEIN; BIOLOGICAL MARKER; FATTY ACID; HYDROXAMIC ACID; INSULIN; LEPTIN; PROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FATTY ACID SYNTHESIS; FATTY LIVER; GENE EXPRESSION; HEPATOMEGALY; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER HISTOLOGY; LIVER RESECTION; MALE; NONHUMAN; OBESITY; POSTOPERATIVE COMPLICATION; RAT; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; BLOOD; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENETICS; INJURY; LIPID DIET; LIVER; METABOLISM; MOUSE; PATHOLOGY; TIME; TREATMENT OUTCOME;

ANIMALIA; MUS;

ADAM PROTEINS; ADIPOKINES; ANIMALS; BIOLOGICAL MARKERS; DIET, HIGH-FAT; FATTY ACIDS; FATTY LIVER; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION; HEPATECTOMY; HYDROXAMIC ACIDS; INSULIN; INSULIN RESISTANCE; LEPTIN; LIVER; MALE; MICE; MICE, INBRED C57BL; OBESITY; PROTEASE INHIBITORS; RNA, MESSENGER; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TREATMENT OUTCOME;

EID: 80053187053     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025587     Document Type: Article

References (41)

1. Angulo P, (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231.
2. Lazo M, Clark JM, (2008) The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 28: 339-350.
3. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH, (2009) Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 51: 371-379.
4. Jou J, Choi SS, Diehl AM, (2008) Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 28: 370-379.
5. Neuschwander-Tetri BA, (2010) Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites. Hepatology 52: 774-788.
6. Adam R, Hoti E, (2009) Liver transplantation: the current situation. Semin Liver Dis 29: 3-18.
7. de Meijer VE, Kalish BT, Puder M, IJzermans JNM, (2010) Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg 97: 1331-1339.
8. Selzner M, Clavien PA, (2001) Fatty liver in liver transplantation and surgery. Semin Liver Dis 21: 105-113.
9. Vuppalanchi R, Chalasani N, (2009) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 49: 306-317.
10. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, et al. (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362: 1675-1685.
11. Sanyal AJ, (2005) Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2: 46-53.
12. Tilg H, Moschen AR, (2008) Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 19: 371-379.
13. Hotamisligil GS, (2006) Inflammation and metabolic disorders. Nature 444: 860-867.
14. Murphy G, Murthy A, Khokha R, (2008) Clipping, shedding and RIPping keep immunity on cue. Trends Immunol 29: 75-82.
15. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS, (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389: 610-614.
16. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729-733.
17. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, et al. (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385: 733-736.
18. Amour A, Slocombe PM, Webster A, Butler M, Knight CG, et al. (1998) TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 435: 39-44.
19. Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR, (2007) Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci USA 104: 19796-19801.
20. Fiorentino L, Vivanti A, Cavalera M, Marzano V, Ronci M, et al. (2010) Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. Hepatology 51: 103-110.
21. Menghini R, Menini S, Amoruso R, Fiorentino L, Casagrande V, et al. (2009) Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 136: 663-672.
22. Doggrell SA, (2002) TACE inhibition: a new approach to treating inflammation. Expert Opin Investig Drugs 11: 1003-1006.
23. Togashi N, Ura N, Higashiura K, Murakami H, Shimamoto K, (2002) Effect of TNF-alpha-converting enzyme inhibitor on insulin resistance in fructose-fed rats. Hypertension 39: 578-580.
24. de Meijer VE, Le HD, Meisel JA, Sharif MR, Pan A, et al. (2010) Dietary fat intake promotes the development of hepatic steatosis independently from excess caloric consumption in a murine model. Metabolism 59: 1092-1105.
25. de Meijer VE, Le HD, Meisel JA, Puder, (2010) Repetitive orogastric gavage affects the phenotype of diet-induced obese mice. Physiol Behav 100: 387-393.
26. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, et al. (1995) Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269: 543-546.
27. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, et al. (1995) Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269: 540-543.
28. Alwayn IP, Verbesey JE, Kim S, Roy R, Arsenault DA, et al. (2008) A critical role for matrix metalloproteinases in liver regeneration. J Surg Res 145: 192-198.
29. Greene AK, Puder M, (2003) Partial hepatectomy in the mouse: technique and perioperative management. J Invest Surg 16: 99-102.
30. Muniyappa R, Lee S, Chen H, Quon MJ, (2008) Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 294: E15-26.
31. Otway S, Robinson DS, (1967) The use of a non-ionic detergent (Triton WR 1339) to determine rates of triglyceride entry into the circulation of the rat under different physiological conditions. J Physiol 190: 321-332.
32. Hong F, Radaeva S, Pan HN, Tian Z, Veech R, et al. (2004) Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 40: 933-941.
33. Federici M, Hribal ML, Menghini R, Kanno H, Marchetti V, et al. (2005) Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 115: 3494-3505.
34. Serino M, Menghini R, Fiorentino L, Amoruso R, Mauriello A, et al. (2007) Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 56: 2541-2546.
35. Marra F, Bertolani C, (2009) Adipokines in liver diseases. Hepatology 50: 957-969.
36. Mohammed FF, Smookler DS, Taylor SE, Fingleton B, Kassiri Z, et al. (2004) Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet 36: 969-977.
37. de Meijer VE, Sverdlov DY, Popov Y, Le HD, Meisel JA, et al. (2010) Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS One 5: e11256.
38. Alwayn IP, Andersson C, Lee S, Arsenault DA, Bistrian BR, et al. (2006) Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. Am J Physiol Gastrointest Liver Physiol 291: G1011-1019.
39. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, et al. (2002) Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 86: 1864-1870.
40. Coussens LM, Fingleton B, Matrisian LM, (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392.
41. Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, et al. (2005) Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clin Cancer Res 11: 4437-4443.